Ritanserin in the treatment of cocaine dependence

Biological Psychiatry

Volumn 42, Issue 10, 1997, Pages 932-940

  Johnson, Bankole A ^a   Chen, Y Richard ^a   Swann, Alan C ^a   Schmitz, Joy ^a   Lesser, Jary ^a   Ruiz, Pedro ^a   Johnson, Philip ^b   Clyde, Christopher ^c  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Cocaine; Dopamine; Humans; Ritanserin; Serotonin; Serotonin 2 antagonist

Indexed keywords

BENZOYLECGONINE; COCAINE; RITANSERIN; SEROTONIN 2 ANTAGONIST;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DEPENDENCE; DRUG EFFICACY; DRUG SAFETY; EDUCATION; ELECTROCARDIOGRAPHY; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTPATIENT CARE; PRIORITY JOURNAL; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

ADULT; COCAINE; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; RITANSERIN; SEROTONIN ANTAGONISTS; SEVERITY OF ILLNESS INDEX; SUBSTANCE-RELATED DISORDERS;

EID: 0030695326     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(96)00490-8     Document Type: Article

References (45)

1. 2 receptors.
2. American Psychiatric Association (1987): Diagnostic and Statistical Manual of Mental Disorders, 3rd ed rev. Washington, DC: American Psychiatric Associations.
3. Bandura A (1977): Self-efficacy: Toward a unifying theory of behavioral change. Psychol Rev 84:191-215.
4. Bandura A (1981): Self-referent thought: A developmental analysis of self-efficacy. In Flavell JH, Ross L (eds), Social Cognitive Development Frontiers and Possible Futures. Cambridge: Cambridge University Press.
5. Bandura A (1982): Self-efficacy mechanism in human agency. Am Psychol 37:122-147.
6. Baumann M, Brockington AM, Rothman, RB (1993): Withdrawal from cocaine enhances behavioral sensitivity to the 5-HT2/1C agonist DOI. Biol Psychiatry 34:576-577.
7. Benloucif S, Keegan MJ, Galloway MP (1993): Serotonin-facilitated dopamine release in vivo: Pharmacological characterization. J Pharmacol Exp Ther 265:373-377.
8. Carroll KM, Rounsaville BJ, Nich C, Gordon LT, Wirtz PW, Gawin F (1994): One-year follow-up of psychotherapy and pharmacotherapy for cocaine dependence. Delayed emergence of psychotherapy effects. Arch Gen Psychiatry 51:989-997.
9. Darmani NA, Martin BR, Glennon RA (1992): Repeated administration of low doses of cocaine enhances the sensitivity of 5-HT2 receptor function. Pharmacol Biochem Behav 41: 519-527.
10. De Wit H, Stewart J (1981): Reinstatement of cocaine-reinforced responding in the rat. Psychopharmacology 75:134-143.
11. Di Chiara G (1995): The role of dopamine in drug abuse viewed from the perspective of its role in motivation. Drug Alcohol Depend 38:95-137.
12. Ehrman RN, Robbins SJ, Childress, AR, O'Brien CP (1992): Conditioned responses to cocaine-related stimuli in cocaine abuse patients. Psychopharmacology 107:523-529.
13. Essman WD, Singh A, Lucki I (1994): Serotonergic properties of cocaine: Effects of 5-HT2 receptor mediated behavior and extracellular concentrations of serotonin and dopamine. Pharmacol Biochem Behav 49:107-113.
14. Guan XM, McBride WJ (1989): Serotonin microinfusion into the ventral tegmental area increases accumbens dopamine release. Brain Res Bull 23:541-547.
15. Guy W (1976): ECDEU Assessment for psychopharmacology revised. DHEW Publication No. (ADM) 76-338. Rockville, MD: NIMH.
16. Hervé D, Pickel VM, Joh TH, Beaudet A (1987): Serotonin axon terminals in the ventral tegmental area of the rat: Fine structure and synaptic input to dopaminergic neurons. Brain Res 435:71-83.
17. Higgins ST, Budney AJ, Bickel WK, Hughes JR, Foerg F, Badger G (1993): Achieving cocaine abstinence with a behavioral approach. Am J Psychiatry 150:763-769.
18. Higgins ST, Budney AJ, Bickel WK (1994): Applying behavioral concepts to the treatment of cocaine dependence. Drug Alcohol Depend 34:87-97.
19. Hoffman JA, Caudill BD, Koman JJ III, Luckey JW, Flynn PM, Hubbard RL (1994): Comparative cocaine abuse treatment strategies: Enhancing client retention and treatment exposure. Addict Dis 13:115-128.
20. Investigational New Drug Brochure (1993): Ritanserin (R 55 667). Janssen Research Foundation.
21. Jaffe JH, Cascella NG, Kumor KM, Sherer MA (1989): Cocaine-induced craving. Psychopharmacology 97:59-64.
22. Javaid JI, Sahni SK, Pandey SC, Davis JM (1993): Repeated cocaine administration does not affect 5-HT receptor sub-types (5-HT1A, 5-HT2) in several brain regions. Eur J Pharmacol 238:425-429.
23. 3 receptor interactions in animals and humans. Drug Dev Res 30:153-169.
24. Koob GF (1992): Drugs of abuse: Anatomy, pharmacology and function of reward pathways. Trends Pharmacol Sci 131:177-184.
25. Levy AD, Li Q, Alvarez-Sanz MC, Rittenhouse PA, Brownfield MS, Van de Kar LD (1992): Repeated cocaine administration modifies neuroendocrine responses to the 5-HT1c/5-HT2 receptor against DOI. Eur J Pharmacol 221:121-127.
26. Marlatt GA, Gordon JR (eds) (1985): Relapse Prevention. New York: Guildford Press.
27. McLellan AT, Kushner H, Metzger D, Peters R, Smith I, Grissom G, Pettinati H, Argeriou M (1992): The fifth edition of the Addiction Severity Index. J Subst Abuse Treat 9:199-213.
28. McMillen BA, Jones EA, Hill LJ, Williams HL, Bjork A, Myers RD (1993): Amperozide, a 5-HT2 antagonist, attenuates cocaine craving by rats. Pharmacol Biochem Behav 46:125-129.
29. Meert TF, Awouters F, Niemegeers CJE, Schellekens KHL, Janssen PAJ (1991): Ritanserin reduces abuse of alcohol, cocaine, and fentanyl in rats. Pharmacopsychiatry 24:159-163.
30. Monti JM, Alterwain P (1991): Ritanserin decreases alcohol intake in chronic alcoholics. Lancet 337:60.
31. Nedergaard S, Bolam JP, Greenfield SA (1988): Do nigro-striatal neurones possess a discrete dendritic modulatory mechanism? Electrophysiological evidence from actions of amphetamine in brain slices. Nature 333:174-177.
32. Parsons LH, Justice JB Jr (1993): Perfusate serotonin increases extracellular dopamine in the nucleus accumbens as measured by in vivo microdialysis. Brain Res 606:195-199.
33. Peltier RL, Emmett-Oglesby MW, Thomas WH, Schenck S (1994): Failure of ritanserin to block the discriminative and reinforcing stimulant effects of cocaine. Pharmacol Biochem Behav 48:473-478.
34. Preston KL, Sullivan JT, Strain EC, Bigelow CE (1992): Effects of cocaine alone and in combination with bromocriptine in human cocaine abusers. J Pharmacol Exp Ther 262:279-291.
35. SAS (1989): SAS/STAT Users Guide, Version 6, 4th ed, vol 1. Cary, NC: SAS Institute Inc.
36. Self DW, Barnhart WJ, Lehman DA, Nestler EJ (1996): Opposite modulation of cocaine-seeking behavior by D1-like and D2-like dopamine receptor agonists. Science 271:1586-1589.
37. Spitzer RL, Robert L, Williams JB, Gibbon M, First MB (1992): The structured clinical interview for DSM III-R (SCID): I. History, rationales, and description. Arch Gen Psychiatry 49:624-629.
38. Sullivan JT, Testa MP, Preston KL, Blum P (1993): Psychoactivity of ritanserin and its interaction with cocaine. College on Problems of Drug Dependence, 55th Annual Scientific Meeting, June 12-17, Toronto, Canada.
39. 2 receptor antagonist activates midbrain dopamine neurons by blocking serotonergic inhibition. Psychopharmacology 98: 45-50.
40. US Department of Health and Human Services (1992): Cognitive-behavioral coping skills therapy. NIAAA project monograph series 3. Washington, DC.
41. Vande Velde P, Van Rooy P, Gelders Y, et al (1987): Multiple-dose pharmacokinetics and dose proportionality of ritanserin after oral administration of 5, 10, and 20 mg once daily for 7 days to healthy volunteers. Clinical Research Report, Janssen Research Foundation.
42. Van Peer A, Gasparini R, Woestenborgs R, Heykants J, Gelders Y (1985): Pharmacokinetics and oral bioavailability of ritanserin (R 55 667) after intravenous and oral administration in healthy volunteers. Clinical Research Report on R 55 667/3, Janssen Research Foundation.
43. Williams JB, Gibbon M, First MB, et al (1992): The structured clinical interview for DSM III-R (SCID): II Multi-site test-retest reliability. Arch Gen Psychiatry 49:630-636.
44. Wise RA, Bozarth MA (1987): A psychostimulant theory of addiction. Psychol Rev 94:469-492.
45. Yoshimoto K, McBride WJ (1991): Regulation of nucleus accumbens dopamine release by the dorsal raphe nucleus in the rat. Neurochem Res 17:401-407.